Missouri Department of Health and Senior Services, Division of Community and Public Health, Office of Epidemiology, Jefferson City, Missouri (Drs Homan and Gwanfogbe); Missouri Department of Mental Health, Jefferson City, Missouri (Dr Yun); School of Medicine, Department of Health Management and Informatics, University of Missouri, Columbia, Missouri (Mr Bouras and Dr Schmaltz); Office of Social and Economic Data Analysis, University of Missouri, Columbia, Missouri (Mr Bouras); Missouri Cancer Registry and Research Center, University of Missouri, Columbia, Missouri (Dr Schmaltz); and Center for Health Policy, University of Missouri, Columbia, Missouri (Ms Lucht).
J Public Health Manag Pract. 2021 Jan/Feb;27(1):70-79. doi: 10.1097/PHH.0000000000001041.
The National Breast and Cervical Cancer Early Detection Program has increased access to screening services for low-income females since 1991; however, evaluation information from states implementing the program is sparse. This study evaluates the impact of the Missouri program, Show Me Healthy Women (SMHW), on early detection and treatment cost.
To estimate breast cancer treatment and health care services costs by stage at diagnosis among Missouri's Medicaid beneficiaries and assess the SMHW program impact.
Analyzed Missouri Medicaid claims linked with Missouri Cancer Registry data for cases diagnosed 2008-2012 (N = 1388) to obtain unadjusted and incremental costs of female breast cancer treatment and follow-up care at 6, 12, and 24 months following diagnosis. Noncancer controls (N = 3840) were matched on age, race, and disability to determine usual health care cost. Regression analyses estimated the impact of stage at diagnosis on expenditures and incremental cost. Show Me Healthy Women participants were compared with other breast cancer patients on stage at diagnosis. A comparison of SMHW participants to themselves had they not been enrolled in the program was analyzed to determine cost savings.
Expenditures increased by stage at diagnosis from in situ to distant with unadjusted cost at 24 months ranging from $50 245 for in situ cancers to $152 431 for distant cancers. Incremental costs increased by stage at diagnosis from 6 months at $7346, $11 859, $21 501, and $20 235 for in situ, localized, regional, and distant breast cancers, respectively, to $9728, $17 056, $38 840, and $44 409 at 24 months. A significantly higher proportion of SMHW participants were diagnosed at an early stage resulting in lower unadjusted expenditures and cost savings.
Although breast cancer treatment costs increased by stage at diagnosis, the population screening program's significant impact on early diagnosis resulted in important cost savings over time for Medicaid.
自 1991 年以来,国家乳腺癌和宫颈癌早期检测计划增加了低收入女性的筛查服务机会;然而,实施该计划的各州的评估信息很少。本研究评估了密苏里州计划“展示健康的密苏里女性”(SMHW)对早期检测和治疗成本的影响。
通过诊断时的阶段估计密苏里州医疗补助受益人的乳腺癌治疗和医疗保健服务成本,并评估 SMHW 计划的影响。
分析了密苏里州医疗补助索赔与密苏里州癌症登记处数据的链接,以获得 2008-2012 年诊断的病例(N=1388),以获得女性乳腺癌治疗和诊断后 6、12 和 24 个月随访护理的未经调整和增量成本。非癌症对照(N=3840)按年龄、种族和残疾情况进行匹配,以确定常规医疗保健费用。回归分析估计了诊断时的阶段对支出和增量成本的影响。将 SMHW 参与者与其他乳腺癌患者进行了比较,这些患者的诊断阶段也不同。分析了与自己相比未参加该计划的 SMHW 参与者的成本节约情况。
未经调整的 24 个月支出随着诊断时的阶段从原位癌到远处转移而增加,从原位癌的 50245 美元到远处转移癌的 152431 美元不等。增量成本从 6 个月开始,随着诊断阶段的增加而增加,从原位癌的 7346 美元、局部癌的 11859 美元、区域癌的 21501 美元和远处癌的 20235 美元,分别增加到 24 个月时的 9728 美元、17056 美元、38840 美元和 44409 美元。参加 SMHW 的患者中有相当大比例的患者被诊断为早期,从而导致未经调整的支出较低,节省了成本。
尽管乳腺癌治疗成本随着诊断时的阶段而增加,但该人群筛查计划对早期诊断的显著影响导致医疗补助的成本随着时间的推移而显著节省。